series-c-plus
Stage
1
Investors
About
Skye Bioscience is a biotechnology company developing next-generation drugs to treat obesity and other metabolic diseases by modulating G-protein coupled receptors. Its pipeline includes nimacimab, a CB1 receptor inhibitor aimed at reducing excess body fat and improving metabolic health.
Explore Skye Bioscience, Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.